Loading clinical trials...
Loading clinical trials...
The Effect of Chemotherapy on Aging in Older Women With Breast Cancer as Measured by Expression of p16INK4a
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors understand how well patients respond to treatment. PURPOSE: This research study is studying biomarkers in blood samples from older women with stage I, stage II, or stage III breast cancer who have finished primary therapy or breast cancer survivors.
OBJECTIVES: Primary * To measure and compare normalized p16\^INK4a gene expression in women ≥ 65 years of age with stage I-III breast cancer who have completed primary therapy comprising surgery with or without radiotherapy followed by endocrine therapy (cohort 2) versus surgery with or without radiotherapy followed by chemotherapy and with or without endocrine therapy (cohort 3) . * To measure and compare normalized p16\^INK4a gene expression in women ≥ 65 years of age with stage I-III breast cancer who have completed primary therapy comprising surgery with or without radiotherapy (cohort 1) versus women treated in cohort 2. * To compare normalized p16\^INK4a gene expression between cohorts 1, 2, and 3 versus an age-matched contemporaneous control group of healthy volunteers accrued from a separate study (cohort 4). Secondary * To access functional status (ability to live independently at home and in the community), co-morbid medical conditions, cognition, psychological status, social functioning and support, medication review, nutritional status, and health-behavior status of these patients. Tertiary (exploratory) * To compare methodologies of p16 \^INK4a gene expression measurement in 50 patients in order to develop a batchable and analytically validated assay that eliminates the need for rapid sample processing. * To explore any association between p16\^INK4a expression and amount of vigorous physical activity, smoking habits, and/or weekly alcohol consumption. * To explore any association between p16\^INK4a expression and type of chemotherapy received, co-morbidities, concomitant medications, and/or tumor characteristics. * To correlate p16\^INK4a expression with scores from selected domains of the Geriatric Assessment (i.e., cognitive function, activities of daily living (ADL), and the instrumental ADL. OUTLINE: Breast cancer survivors and healthy volunteers undergo blood collection for p16\^INK4a gene expression analysis by Taqman RT-PCR. Breast cancer survivors complete the Health Behavior and the Geriatric Assessment Questionnaires. They also complete a Timed Up and Go test to determine physical mobility. Medical charts are reviewed to record information about diagnosis and treatment.
Age
50 - No limit years
Sex
FEMALE
Healthy Volunteers
No
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, United States
Start Date
January 1, 2010
Primary Completion Date
January 1, 2013
Completion Date
February 1, 2014
Last Updated
February 27, 2014
246
ACTUAL participants
gene expression analysis
GENETIC
reverse transcriptase-polymerase chain reaction
GENETIC
laboratory biomarker analysis
OTHER
medical chart review
OTHER
questionnaire administration
OTHER
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
NCT05673200
NCT05245812
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions